Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
about
Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studiesDipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studiesAlogliptin benzoate for management of type 2 diabetesDipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participantsDipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trialsCardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review.Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus.Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study.Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials.Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats.Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials.Triple therapy in type 2 diabetes; a systematic review and network meta-analysis.Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptinDipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials.Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes MellitusThe pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.Alogliptin (nesina) for adults with type-2 diabetes.Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.A review of gliptins in 2011.Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.Alogliptin.Alogliptin: safety, efficacy, and clinical implications.Alogliptin benzoate for the treatment of type 2 diabetes.Meta-analysis of the cardiovascular outcomes with dipeptidyl peptidase 4 inhibitors: validation of the current FDA mandate.Implications of incretin-based therapies on cardiovascular disease.A review of gliptins for 2014.Pharmacologic treatment of type 2 diabetes: oral medications.Alogliptin: a review of its use in patients with type 2 diabetes mellitus.Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus.Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes.Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation.NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis.Pharmacotherapy of 'treatment resistant' type 2 diabetes.Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus.Effect of Long-term Incretin-Based Therapies on Ischemic Heart Diseases in Patients with Type 2 Diabetes Mellitus: A Network Meta-analysis.
P2860
Q24288949-5F140562-4B1B-425B-8FF5-7A87BCCFD4D4Q26765047-2C2706EF-0F13-4D59-9FB2-66E6D763D542Q28083933-D4046CFF-6750-4525-A42B-01F83ECFE31BQ28238585-E0E26927-F0FB-4961-852F-66D4809DFFF4Q28294225-9758A026-DB3E-4C2F-82D0-D5BF967A3E5FQ30241808-1D73662D-8AEA-4578-936E-E4EB1255254BQ33874654-E8ED6635-A218-49A3-A8CE-4418FDAC0D23Q34457919-3E8E1C11-1CCC-44E0-9258-06F8F123765DQ34637776-14492760-7F2F-45D5-AFE9-350EB956E58EQ35236019-03FF0724-FB06-4EF0-B69D-BE055B1DFED5Q35688028-AA8331D4-E010-4D06-ACEF-739A82EB071EQ36315963-3BDB3395-12C5-4268-BAD1-F1C6A8223A9AQ36361872-7C457E5F-F5CF-46AC-8CA8-94A37CE0DBD1Q36706802-DA44C615-E6DD-4BF4-AD5A-ECA49884A026Q37072773-9D140200-E422-4317-B838-3230FCFD3E3EQ37195882-E5BC57FC-25E3-4956-BEBE-D7BABD9A5074Q37427309-4326DA83-C588-4730-BD59-B90A568C7149Q37639487-CE55D9FA-DEEB-4F26-BF2B-2833EA638B82Q37733244-2C9A235D-F889-4DE1-BC96-9B3289EC128FQ37737474-AC68A331-992B-4299-AACA-FB9FCDAED614Q37965612-E77DD571-396B-4E46-803E-95247E7AD109Q38167010-D3AA96B6-011E-4332-B101-B9F6C7FAF6E9Q38178240-B8B3D76A-0834-4469-B9CE-98973C3FD987Q38188548-A571CFBC-1071-48A5-880F-C24604841FE5Q38197275-7D1D7DEF-0D59-489A-A838-44E4EF8D5CCBQ38200923-AF4F90B6-A644-4628-8CCC-4D417DA2C123Q38264374-CE82DB60-A329-4BA4-B245-9620A3100FF7Q38266290-FF45963F-86A5-47A3-8D72-86302DB6F56AQ38350347-574D21F5-5CA8-4617-B4BD-3C6B5EE80939Q38412153-B61F4EB5-57C1-4327-81D0-1BC5FBEE23E6Q38455771-3B922639-A0B3-4739-BD56-1B9F1BDED9FAQ38468017-29C66DD4-D44B-49B0-A93E-225E19D4B896Q38546981-F7C95D3A-9E12-4941-BFC6-AAD4714C085EQ38556037-A29E9E04-2814-47D8-B0CB-0CD5537E07C6Q38603506-0B9A53DB-0CA6-4E63-8075-9EA865C37ADFQ38647717-8800C7AE-5259-47E6-A5F3-9B6E462A0247Q38778476-107C2C6C-DBFB-469A-AA87-C2D102CDFCC0Q39170345-00C0557A-15C7-4023-BF48-F0703E3354F2Q39451977-6BC49D18-BEB9-4F58-B141-ABC4C131546EQ47136714-06CEE1AF-AEBD-4756-A735-E589A9837EDB
P2860
Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Alogliptin as a third oral ant ...... trolled, parallel-group study.
@en
Alogliptin as a third oral ant ...... trolled, parallel-group study.
@nl
type
label
Alogliptin as a third oral ant ...... trolled, parallel-group study.
@en
Alogliptin as a third oral ant ...... trolled, parallel-group study.
@nl
prefLabel
Alogliptin as a third oral ant ...... trolled, parallel-group study.
@en
Alogliptin as a third oral ant ...... trolled, parallel-group study.
@nl
P2093
P2860
P921
P1476
Alogliptin as a third oral ant ...... trolled, parallel-group study.
@en
P2093
P2860
P304
P356
10.1111/J.1463-1326.2011.01463.X
P577
2011-12-01T00:00:00Z